medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 4

<< Back Next >>

Arch Neurocien 2023; 28 (4)

Mechanisms of nerve regeneration for drug-resistant epilepsy: scoping review protocol

García-González R, Sandoval H, Mishra R, Malvaso A, Alarcon-Ruiz CA, Ríos C, Pérez-Neri I

Language: English
References: 42
Page: 29-34
PDF size: 239.51 Kb.


ABSTRACT

Drug-resistant epilepsy, affecting 30 to 40 percent of epilepsy patients, is described by the International League Against Epilepsy as “the failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules”. This condition affects patients’ quality of life and increases their mortality risk. Individuals with drug-resistant epilepsy may remain unable to achieve seizure independence until progressive degeneration is halted, and the regulatory function of interneurons is restored. Recent studies have developed techniques for modulating signaling pathways related to neural regeneration in the central nervous system, encompassing the regrowth or repair of nervous tissues, cells, or cell products. This scoping review protocol aims to evaluate the therapeutic potential of interventions that modulate nerve regeneration pathways for patients with drug-resistant epilepsy. Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, EBSCOhost, Ovid, and Google Scholar, spanning from database inception to the present. Studies describing patients or experimental models of drug-resistant epilepsy receiving treatments that modulate nerve regeneration pathways will be included. Studies in languages other than Spanish or English that cannot be appropriately translated or whose full-text files cannot be retrieved despite exhaustive efforts will be excluded. Eligibility assessment will be performed independently by two researchers, and results will be presented in tables. A narrative synthesis of the findings will be provided.


REFERENCES

  1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH,Elger CE, et al. ILAE official report: a practical clinical definitionof epilepsy. Epilepsia. 2014;55(4):475-82.

  2. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W,Mathern, G et al. Definition of drug resistant epilepsy: consensusproposal by the ad hoc Task Force of the ILAE Commission onTherapeutic Strategies. Epilepsia. 2010;51(6):1069-77.

  3. Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. Theepidemiology of drug-resistant epilepsy: A systematic review andmeta-analysis. Epilepsia. 2018;59(12):2179-93.

  4. Fang M, Xi Z-Q, Wu Y, Wang X-F. A new hypothesis of drugrefractory epilepsy: Neural network hypothesis. Med Hypotheses.2011;76(6):871-6.

  5. Bazhanova ED, Kozlov AA, Litovchenko AV. Mechanismsof drug resistance in the pathogenesis of epilepsy: roleof neuroinflammation. A literature review. Brain Sci.2021;11(5):663.

  6. Bernard C, Cossart R, Hirsch JC, Esclapez M, Ben-Ari Y. What isGABAergic inhibition? How is it modified in epilepsy. Epilepsia.2000;41 Suppl 6:S90-5.

  7. Yoo JY, Panov F. Identification and treatment of drug-resistantepilepsy. Continuum (Minneap Minn). 2019;25(2):362-80.

  8. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized,controlled trial of surgery for temporal-lobe epilepsy. N Engl JMed. 2001;345(5):311-8.

  9. Sheng J, Liu S, Qin H, Li B, Zhang X. Drug-resistant epilepsy andsurgery. Curr Neuropharmacol. 2018;16(1):17-28.

  10. Krahl S. Vagus nerve stimulation for epilepsy: A review of theperipheral mechanisms. Surgical Neurology International.2012;3(2):47.

  11. Wang X, So K-F, Xu X-M. Advances and challenges for neuralregeneration research. In: So K-F, Xu X-M, editors. NeuralRegeneration. Elsevier; 2015. p. 3-17.

  12. Curcio M, Bradke F. Axon regeneration in the central nervoussystem: facing the challenges from the inside. Annu Rev Cell DevBiol. 2018;34:495-521.

  13. White AR, Tiwari D, MacLeod MC, Danzer SC, Gross C. PI3Kisoform-selective inhibition in neuron-specific PTEN-deficientmice rescues molecular defects and reduces epilepsy-associatedphenotypes. Neurobiol Dis. 2020;144:105026.

  14. Jaworski T. Control of neuronal excitability by GSK-3beta:Epilepsy and beyond. Biochim Biophys Acta Mol Cell Res.2020;1867(9):118745.

  15. Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, Campos-Peña V. GSK3β and tau protein in Alzheimer’s disease andepilepsy. Front Cell Neurosci. 2020;14:19.

  16. Han CL, Ge M, Liu YP, Zhao XM, Wang KL, Chen N, et al.LncRNA H19 contributes to hippocampal glial cell activation viaJAK/STAT signaling in a rat model of temporal lobe epilepsy. JNeuroinflammation. 2018;15(1):103.

  17. Asghari Adib E, Smithson LJ, Collins CA. An axonal stressresponse pathway: degenerative and regenerative signaling byDLK. Curr Opin Neurobiol. 2018;53:110-9.

  18. Arksey H, O’Malley L. Scoping studies: towards a methodologicalframework. Int J Soc Res Methodol. 2005;8(1):19-32.

  19. Pérez-Neri I, Diéguez-Campaa CE, Sandoval H, ChávezVA, Castro-Martínez E, Ríos C. Therapeutic potential ofdehydroepiandrosterone for Parkinson’s disease: scoping reviewprotocol. Arch Neurocien. 2022;27(2):39-46.

  20. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s disease inRomania: a scoping review protocol. Brain Sci. 2021;11(2):251.

  21. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, MulrowCD, et al. PRISMA 2020 explanation and elaboration: updatedguidance and exemplars for reporting systematic reviews. BMJ.2021;372:n160.

  22. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H,Chalmers I, et al. PRISMA for Abstracts: reporting systematicreviews in journal and conference abstracts. PLoS Med.2013;10(4):e1001419.

  23. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, PetticrewM, et al. Preferred reporting items for systematic review andmeta-analysis protocols (PRISMA-P) 2015: elaboration andexplanation. BMJ. 2015;350:g7647.

  24. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, etal. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklistand explanation. Ann Intern Med. 2018;169(7):467-73.

  25. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis.JBI; 2020.

  26. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G,Buttery SC, Chynkiamis N, et al. Walking-related digital mobilityoutcomes as clinical trial endpoint measures: protocol for ascoping review. BMJ Open. 2020;10(7):e038704.

  27. Petticrew M, Roberts H. Systematic reviews in the social sciences.Malden: Wiley-Blackwell; 2005.

  28. Shah SGS, Nogueras D, van Woerden H, Kiparoglou V.Effectiveness of digital technology interventions to reduceloneliness in adults: a protocol for a systematic review and metaanalysis.BMJ Open. 2019;9:e032455.

  29. Strech D, Synofzik M, Marckmann G. Systematic reviews ofempirical bioethics. J Med Ethics. 2008;34(6):472-7.

  30. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodologicalguidance for systematic reviews of observational epidemiologicalstudies reporting prevalence and cumulative incidence data. Int JEvid Based Healthc. 2015;13(3):147-53.

  31. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D,Page MJ, et al. PRISMA-S: an extension to the PRISMA Statementfor Reporting Literature Searches in Systematic Reviews. Syst Rev.2021;10(1):39.

  32. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V,Lefebvre C. PRESS Peer Review of Electronic Search Strategies:2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-6.

  33. Bramer W, de Jonge GB. Improving efficiency and confidence insystematic literature searching. European Association for HealthInformation and Libraries (EAHIL). Sevilla, 2016.

  34. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. Theocular surface, coronaviruses and COVID ‐19. Clin Exp Optom.2020;103(4):418-24.

  35. Takakusagi Y, Oike T, Shirai K, Sato H, Kano K, Shima S, et al.Validation of the reliability of machine translation for a medicalarticle from Japanese to English using DeepL translator. Cureus.2021;13(9):e17778.

  36. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C, RíosC. Therapeutic potential of ultrasound neuromodulation indecreasing neuropathic pain: clinical and experimental evidence.Curr Neuropharmacol. 2021;19(3):334-48.

  37. McKeown S, Mir ZM. Considerations for conducting systematicreviews: evaluating the performance of different methods forde-duplicating references. Syst Rev. 2021;10(1):38.

  38. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J,Luechtefeld T. Sysrev: A FAIR platform for data curation andsystematic evidence review. Front Artif Intell. 2021;4:685298.

  39. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, HamelC, Kamel C, et al. Cochrane Rapid Reviews Methods Groupoffers evidence-informed guidance to conduct rapid reviews. JClin Epidemiol. 2021;130:13-22.

  40. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA.PRISMA2020: An R package and Shiny app for producingPRISMA 2020‐compliant flow diagrams, with interactivity foroptimised digital transparency and Open Synthesis. CampbellSyst Rev. 2022;18(2).

  41. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, etal. Applying an equity lens to interventions: using PROGRESSensures consideration of socially stratifying factors to illuminateinequities in health. J Clin Epidemiol. 2014;67(1):56-64.

  42. Usher R, Stapleton T. Approaches for assessing decision-makingcapacity in older adults: a scoping review protocol. JBI EvidenceSynthesis. 2020;18(4):832-40.




2020     |     www.medigraphic.com